A pilot study of thymosin α1 therapy for chronic hepatitis B patients

Internal Medicine

Volumn 42, Issue 10, 2003, Pages 941-946

  Arase, Yasuji ^a   Tsubota, Akihito ^a   Suzuki, Yoshiyuki ^a   Suzuki, Fumitaka ^a   Kobayashi, Masahiro ^a   Someya, Takashi ^a   Akuta, Norio ^a   Hosaka, Tetsuya ^a   Saitoh, Satoshi ^a   Ikeda, Kenji ^a   Kobayashi, Mariko ^a   Kumada, Hiromitsu ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

Chronic hepatitis B; HBV DNA; Thymosin alpha 1

Indexed keywords

ALANINE AMINOTRANSFERASE; DRUG DERIVATIVE; GAMMA INTERFERON; HEPATITIS B(E) ANTIGEN; IMMUNOLOGICAL ADJUVANT; INTERFERON; INTERLEUKIN 2; LAMIVUDINE; THYMOSIN; THYMOSIN ALPHA(1); THYMOSIN ALPHA1; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EDEMA; FEMALE; GENE AMPLIFICATION; HEPATITIS B; HISTOLOGY; HUMAN; IMMUNOLOGY; IMMUNOMODULATION; JAUNDICE; LEUKOPENIA; LIVER FAILURE; LOW DRUG DOSE; MALE; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; PILOT STUDY; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE ACTIVATION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 10744231838     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.42.941     Document Type: Article

References (23)

1. Aikawa T, Sairenji H, Furuta S, et al. Seroconversion from hepatitis B e antigen to anti-HBe in acute hepatitis B virus infection. N Engl J Med 298: 439-441, 1978.
2. Realdi G, Alberti A, Rogge M, et al. Seroconversion from hepatitis B e antigen to anti-HBe in chronic hepatitis B virus infection. Gastroenterology 79: 195-199, 1980.
3. Hoofnagle JH, Dusheiko GM, Seeff LB, Jones EA, Waggoner JG, Bales ZB. Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Ann Intern Med 94: 744-748, 1981.
4. Lam KC, Lai CL, Trepo C, Wit PC. Deleterious effect of prednisolone in HBsAg-positive chronic active hepatitis. N Engl J Med 304: 380-386, 1981.
5. Naylor PH, Mutchnick MG. Thymus derived peptides in the treatment of viral chronic hepatitis. Dig Dis Sci 14: 362-370, 1996.
6. 1 in patients with chronic hepatitis B: a randomized, controlled trial. Hepatology 27: 1383-1387, 1998.
7. 1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled study. J Viral Hepatitis 6: 397-403, 1999.
8. Mutchnick MG, Appelman HD, Chung HT, et al. Thymosin treatment of chronic hepatitis B: a placebo-controlled pilot trial. Hepatology 14: 409-415, 1991.
9. 1 versus interferon alpha treatment in patients with hepatitis B e antigen antibody-and hepatitis B virus DNA-positive chronic hepatitis B. Hepatology 24: 774-777, 1996.
10. Usuda S. Okamoto H. Iwanari H, et al. Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in the pre S2-region product. J Virol Methods 80: 97-112, 1999.
11. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 19: 1513-1520, 1994.
12. Korenman J, Baker B, Waggoner J, Everhart JE, Di Bisceglie AM, Hoofnagle JH. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 114: 629-634, 1991.
13. Tine F, Liberati A, Craxi A, Almasio P, Pagliaro L. Interferon treatment in patients with chronic hepatitis B: A meta-analysis of the published literature. J Hepatol 18: 154-162, 1993.
14. Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 336: 347-356, 1997.
15. Niederau C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 334: 1422-1427, 1996.
16. Gregorio GV, Jara P, Hierro L, et al. Lymphoblastoid interferon alfa with or without steroid pretreatment in children with chronic hepatitis B: A multicenter controlled trial. Hepatology 23: 700-707, 1996.
17. Lok AS, Lai CL, Wu PC, Leung EK. Long-term follw-up in a randomised controlled trial of recombinant alpha 2-interferon in Chinese patients with chronic hepatitis B infection. Lancet 2: 298-302, 1988.
18. Lok AS, Lai CL, Wu PC, et al. Alpha-interferon treatment in Chinese patients with chronic hepatitis B. J Hepatol 11: 121-125, 1990.
19. Yokosuka O, Omata M, Imazeki F, Okuda K, Summers J. Changes of hepatitis B virus DNA in liver and serum caused by recombinant leukocyte interferon treatment: analysis of intrahepatic replicative hepatitis B virus DNA. Hepatology 5: 728-734, 1985.
20. Chayama K, Suzuki Y, Kobayashi M, et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 27: 1711-1716, 1998.
21. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 30: 567-572, 1999.
22. Mutchnick MG, Prieto JA, Schaffner JA, Weller FE. Thymosin modulation of regulatory T cell function. et al. Clin Immunol Immunopathol 23: 626-633, 1982.
23. Mastino A, Favalli C, Grelli S, Garaci E. Interaction between thymic hormones and other immunomodulatory agents. Ann Ist Super Sanita 27: 51-56, 1991.